证券之星消息，11月19日南向资金增持1.89万股讯飞医疗科技（02506.HK）。近5个交易日中，获南向 资金增持的有4天，累计净增持2.78万股。近20个交易日中，获南向资金增持的有12天，累计净增持 10.21万股。截至目前，南向资金持有讯飞医疗科技（02506.HK）382.81万股，占公司已发行普通股的 4.94%。 讯飞医疗科技股份有限公司是一家主要从事提供人工智能赋能的医疗解决方案的中国公司。基层医疗服 务业务线由智医助理及慢病管理组成。医院服务业务线包括智慧医院解决方案和诊疗助理。患者服务业 务线包括智慧医院患者服务与诊后管理（包括讯飞晓医App及小程序）、影像云平台以及医疗器械。区 域管理平台解决方案业务线包括智慧卫生解决方案和智慧医保。该公司主要在国内市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-19 | 382.81万 | 1.89万 | 0.50% | ...

Core Viewpoint - Southbound funds increased their holdings in iFlytek Medical Technology (02506.HK) by 650.0 shares on November 17, 2025, while experiencing a net reduction of 4,500.0 shares over the past five trading days [1][2]. Group 1: Southbound Fund Activity - In the last 20 trading days, iFlytek Medical Technology saw 12 days of net increases in southbound fund holdings, totaling 82,600 shares [1]. - As of November 17, 2025, southbound funds hold 3.7932 million shares of iFlytek Medical Technology, representing 4.9% of the company's total issued ordinary shares [1][2]. Group 2: Company Overview - iFlytek Medical Technology is primarily engaged in providing AI-powered medical solutions in China, with business lines including grassroots medical services, hospital services, patient services, and regional management platform solutions [2]. - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [2]. - Patient services encompass smart hospital patient services, post-discharge management, imaging cloud platforms, and medical devices [2].

Core Viewpoint - Southbound funds reduced their holdings in iFlytek Medical Technology (02506.HK) by 5,550 shares on October 16, 2025, indicating a slight decrease in investor confidence in the short term [1]. Group 1: Southbound Fund Activity - In the last five trading days, southbound funds increased their holdings on three days, with a total net increase of 85,400 shares [1]. - Over the past 20 trading days, there were 16 days of net increases, totaling 253,400 shares [1]. - As of now, southbound funds hold 3,710,600 shares of iFlytek Medical Technology, accounting for 4.79% of the company's total issued ordinary shares [1]. Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [2]. - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-discharge management) [2]. - The regional management platform solutions include smart health solutions and smart medical insurance [2].

Core Viewpoint - The company primarily operates in the domestic market, providing AI-enabled medical solutions, with business lines including primary healthcare services, hospital services, patient services, and regional management platform solutions [5] Revenue and Profit Growth - Historical revenue and net profit growth rates show fluctuations, with a notable increase in revenue growth rate in 2023 compared to previous years [7][10] - The company's revenue for the first half of 2025 is composed of various segments: hospital solutions (0.529 billion), patient management services (1.043 billion), regional solutions (0.576 billion), and primary healthcare solutions (0.838 billion) [9] Financial Performance Metrics - In the first half of 2025, the average return on equity was -8.2%, an increase of 20.62 percentage points from the same period last year [14] - The company's total asset turnover ratio has shown a consistent trend, with a notable value of 0.44 times in 2025H1 [17] Asset and Liability Changes - As of the first half of 2025, significant changes in assets include a 7.7% increase in receivables, a 44.97% increase in long-term receivables, a 28.7% increase in inventory, and a 77.75% increase in contract assets [23] - On the liabilities side, long-term borrowings increased by 224.07%, and short-term borrowings increased by 68.61%, indicating a rise in the proportion of total assets [26] Liquidity Ratios - The company reported a current ratio of 1.60 and a quick ratio of 1.49 in the first half of 2025, indicating a stable liquidity position [29]

本文为IPO早知道原创 核心产品智医助理在中国基层医疗机构CDSS市场中排名第一。 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，科大讯飞（002230.SZ）拟分拆上市的控股子公司讯飞医疗科技股份有限公司 （下称"讯飞医疗"）日前已通过港交所聆讯，华泰国际、广发证券、建银国际担任保荐人。 讯飞医疗为一家人工智能赋能的医疗行业解决方案提供商，其产品及解决方案支持从健康风险预警、 早筛、辅助诊断及治疗以及治疗效果评估、诊后管理与慢病管理的多种医疗服务，现已向约60,000 家基层医疗机构提供产品及服务，涵盖30多个省份610多个区县及500多家等级医院。公司于2023 年的收入规模在中国医疗人工智能行业中排名第一，市场份额5.9%。 讯飞医疗建立了围绕深度神经网络、深度学习和医学知识图谱的核心技术框架，以及语音识别、图像 识别及自然语言理解在医疗领域应用的专有核心技术。 公司专有的讯飞星火大模型，使公司的技术从感知智能向认知智能进化，并在医疗保健行业进一步生 成新内容。该大模型在专家级医学知识图谱问答、临床语言理解、医学文文件生成、疾病诊断及治疗 推荐、多轮医疗对话、多模态交互等六个医学 ...